Accession Number : ADA299661
Title : Reversal of Multidrug Resistance in Breast Cancer.
Descriptive Note : Annual rept.,
Corporate Author : FOX CHASE CANCER CENTER PHILADELPHIA PA
Personal Author(s) : Goldstein, Lori J.
PDF Url : ADA299661
Report Date : 27 JUL 1995
Pagination or Media Count : 71
Abstract : Our data show that MDR'1 gene expression is important in breast cancer resistance. The role of the MDRl gene in breast cancer treatment will be further defined by sequentially determining MDRl gene expression pre and post treatment with doxorubicin in the context of three prospective clinical trials. In addition, this study will allow a correlation of MDRl gene expression and clinical outcome. To determine what level of MDRl gene expression is clinically significant, various molecular methods of determining MDR 1 gene expression, including immunohistochemistry and quantitative reverse transcription followed by polymerase chain reaction, will be evaluated. MDR can be reversed in vitro and we will test this hypothesis in a Phase I study of cyclosporin A and quinine as MDR reversers of vinblastine resistance. Together these studies will address the major goal of circumventing drug resistance in breast cancer. When the data of the MDRl gene expression in breast cancer specimens from this proposal are available, clinical trials incorporating the modulators of MDR, cyclosporin and quinine, will be designed for breast cancer as well. An alteration in drug efflux potentially may have an impact on response to chemotherapy and may result in improved survival for breast cancer patients. During the period between March 15, 1993 and March 14, 1995, we have outfitted our laboratory with staff, equipment, supplies and reagents and have been performing control experiments and have been pursuing activation of the various clinical trials to support this project
Descriptors : *DRUGS, *CHEMOTHERAPY, *CANCER, *MAMMARY GLANDS, *RESISTANCE(BIOLOGY), CONTROL, ACTIVATION, SURVIVAL(GENERAL), IN VITRO ANALYSIS, CHEMISTRY, REVERSIBLE, GENES, HYPOTHESES, PATIENTS, IMMUNOLOGY, PHARMACOLOGY, HISTOLOGY, QUININE.
Subject Categories : Anatomy and Physiology
Distribution Statement : APPROVED FOR PUBLIC RELEASE